Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged Naxitamab Infusion in Relapsed/Refractory Neuroblastoma
NCT07027748Phase 1Recruiting
- Start
- Jun 2025
- Primary completion
- Jul 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naxitamab in neuroblastoma. Primary endpoint: Recommended duration of naxitamab infusion at 21 days. Started Jun 2025; status: recruiting.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT07027748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027748.